ELAB

+ Watchlist + Portfolio

PMGC Holdings Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.36
52-Week Range: $2.59 – $2,671.20
Market Cap: $2.58M
P/E (TTM): —
EPS (TTM): -1748.36
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.12
PEG Ratio: —
Return on Equity: -105.22%
Return on Assets: -32.97%
Gross Margin: -20.51%
Operating Margin: -289.98%
Profit Margin: 0.00%
Current Ratio: 1.36
Debt/Equity: 0.85
Total Debt: $14.24M
Free Cash Flow: $-4.13M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-2.00M

ELAB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$766.28K	$0.00	$0.00	$590.08K
Cost of Revenue	$318.97K	$578.01K	$0.00	$404.77K
Gross Profit	$447.31K	$1.13M	$0.00	$185.31K
Research & Development	$228.75K	$7.41K	$104.65K	$147.01K
Selling, General & Admin	$1.73M	$1.02M	$3.32M	$5.63M
Operating Expenses	$2.24M	$1.13M	$3.66M	$7.01M
Operating Income	-$1.79M	-$1.13M	-$3.66M	-$6.82M
EBITDA	-$1.79M	-$1.65M	-$3.27M	-$7.40M
Pretax Income	-$1.80M	-$1.66M	-$4.02M	-$7.75M
Income Tax	—	—	$0.00	$30.97K
Net Income	-$1.80M	-$4.30M	-$6.25M	-$7.75M
Diluted EPS	-12246.72	-29262.02	-1195.13	-380.99
Diluted Shares	147	147	5226	20335

ELAB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.15M	$3.33M	$3.98M	$5.40M
Receivables	$12.85K	$3.07K	$5.28K	$340.53K
Inventory	$230.15K	$495.67K	—	$95.10K
Current Assets	$1.55M	$4.92M	$6.05M	$6.87M
Total Assets	$1.89M	$5.19M	$8.99M	$12.87M
Current Liabilities	$588.27K	$1.30M	$1.80M	$3.94M
Long-Term Debt	—	—	—	$85.00K
Total Debt	$283.22K	$210.49K	$0.00	$2.64M
Total Liabilities	$760.87K	$1.36M	$2.33M	$5.03M
Retained Earnings	-$2.72M	-$7.02M	-$13.27M	-$21.02M
Shareholders' Equity	$1.13M	$3.83M	$6.66M	$7.84M
Working Capital	$963.05K	$3.62M	$4.25M	$2.93M

ELAB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.59M	-$4.56M	-$5.49M	-$5.93M
Capital Expenditure	-$35.53K	-$11.19K	-$471.48K	-$448.25K
Free Cash Flow	-$1.62M	-$4.57M	-$5.96M	-$6.38M
Depreciation & Amortisation	$6.51K	$11.65K	$12.95K	$96.66K
Stock-Based Compensation	$171.87K	$487.74K	$97.17K	-$19.16K
Investing Cash Flow	-$32.03K	-$11.19K	-$610.56K	-$2.77M
Financing Cash Flow	$2.36M	$6.74M	$6.76M	$10.12M
Share Repurchases	—	—	$0.00	-$179.00
Net Change in Cash	$744.36K	$2.17M	$659.96K	$1.42M

ELAB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$285.95K	$304.14K	$681.99K	$1.31M
Cost of Revenue	$0.00	$0.00	$207.92K	$196.85K	$451.52K	$920.92K
Gross Profit	$0.00	$0.00	$78.03K	$107.28K	$230.47K	$385.69K
Research & Development	$32.43K	$66.67K	$15.00K	$32.90K	$47.06K	$310.22K
Selling, General & Admin	$1.06M	$884.69K	$1.80M	$1.89M	$3.22M	$3.41M
Operating Expenses	$1.20M	$1.01M	$2.27M	$2.52M	$3.55M	$4.20M
Operating Income	-$1.20M	-$1.01M	-$2.19M	-$2.41M	-$3.32M	-$3.82M
EBITDA	-$1.57M	-$579.47K	-$2.56M	-$2.68M	-$4.34M	-$2.07M
Pretax Income	-$1.58M	-$579.49K	-$2.62M	-$2.97M	-$4.99M	-$2.96M
Net Income	-$1.61M	-$562.36K	-$2.59M	-$2.98M	-$4.97M	-$2.94M
Diluted EPS	-248.03	-37.98	-117.82	—	-11.18	-0.60
Diluted Shares	6485	14806	22019	—	444506	4.88M

ELAB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$5.36M	$5.68M	$7.70M	$5.40M	$14.35M	$18.14M
Receivables	$52.14K	$204.32K	$369.43K	$340.53K	$542.72K	$603.49K
Inventory	—	—	$128.47K	$95.10K	$253.56K	$932.51K
Current Assets	$6.82M	$7.30M	$9.77M	$6.87M	$16.39M	$20.83M
Total Assets	$8.89M	$9.38M	$14.94M	$12.87M	$26.03M	$36.56M
Current Liabilities	$760.27K	$326.30K	$5.46M	$3.94M	$11.30M	$15.33M
Long-Term Debt	—	—	—	$85.00K	$359.25K	$274.25K
Total Debt	—	—	$4.41M	$2.64M	$7.96M	$14.24M
Total Liabilities	$760.27K	$326.30K	$6.45M	$5.03M	$13.43M	$19.83M
Retained Earnings	-$14.88M	-$15.44M	-$18.03M	-$21.02M	-$25.98M	-$28.93M
Shareholders' Equity	$8.13M	$9.05M	$8.49M	$7.84M	$12.61M	$16.74M
Working Capital	$6.06M	$6.98M	$4.31M	$2.93M	$5.09M	$5.50M

ELAB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.35M	-$1.35M	-$1.49M	-$1.75M	-$2.98M	-$1.99M
Capital Expenditure	—	—	-$95.59K	-$346.66K	-$363.09K	—
Free Cash Flow	-$1.35M	-$1.35M	-$1.59M	-$2.10M	-$3.34M	-$1.96M
Depreciation & Amortisation	$1.60K	$21.00	$35.28K	$59.76K	$173.90K	$305.40K
Stock-Based Compensation	-$58.84K	$15.84K	$13.18K	$10.66K	$8.22K	$174.54K
Investing Cash Flow	-$215.32K	$196.84K	-$2.20M	-$548.64K	-$2.48M	-$3.68M
Financing Cash Flow	$2.94M	$1.47M	$5.71M	-$1.00	$14.41M	$9.46M
Share Repurchases	-$179.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	$1.38M	$318.13K	$2.02M	-$2.30M	$8.95M	$3.79M

Market Snapshot

About

PMGC Holdings Inc. operates through its subsidiaries in the healthcare and medical device sectors. The company focuses on developing and commercializing innovative medical technologies and solutions. PMGC Holdings works to bring advanced healthcare products to market through strategic partnerships and research collaborations. The company's business model emphasizes addressing unmet needs in the medical device industry through technology development and market access strategies.